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ORIGINAL ARTICLE
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Ari Lepp€aniemia and Ville Sallinena,b
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Transplantation and Liver Surgery, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland; cThe Transplant Institute,
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ABSTRACT
Objectives: In acute portal vein thrombosis (PVT), a six-month anticoagulation treatment achieves
complete recanalization in only 35%–45% of patients, but the predictors of poor treatment responses
are unclear. We examined treatment outcomes in PVT and aimed to identify predictors of incomplete
recanalization and portal hypertensive complications.
Materials and methods: This retrospective study comprised patients diagnosed with PVT between
2006 and 2015. Key exclusion criteria were liver cirrhosis, malignancy, and age <18.
Results: The final cohort comprised 145 patients, of whom 132 (92%) were primarily treated with anti-
coagulation. The 5-year cumulative incidence of complete recanalization was 42% and of portal hyper-
tensive complications, 31%. Independent predictors of insufficient recanalization were sub-acute or
chronic thrombosis (hazard ratio (HR) 3.1, 95% CI 1.6–5.8), while acute pancreatitis was a protective
factor (HR 0.3, 95% CI 0.2 0.7). Independent predictors of incident portal hypertensive complications
were as cites at baseline (HR 3.3, 95% CI 1.7–6.7), sub-acute or chronic thrombosis (HR 2.9, 95% CI
1.6–5.3), extension of thrombosis to the splenic or mesenteric vein (HR 2.6, 95% CI 1.2–5.7), myelopro-
liferative disease (HR 3.0, 95% CI 1.4–6.5), and anemia (HR 2.1, 95% 1.1–3.9), while acute pancreatitis
was a protective factor (HR 0.1, 95% CI 0.03–0.5).
Conclusions: Etiology and age of thrombosis are associated with treatment responses in PVT. The
presence of ascites at baseline, etiology, and extent of thrombosis, a non-acute thrombosis and
anemia, are associated with the risk of portal hypertensive complications. Etiology and extent of
thrombosis should be taken into account when determining the treatment (method) for PVT.
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Portal vein thrombosis (PVT) can be categorized according to
age of thrombosis, completeness of obstruction, and extent
of thrombosis. The aim of treatment was to determine the
etiological factors, prevent the expansion of thrombosis, and
restore portal vein circulation. Thrombosis restricted to the
portal vein is usually treated with anticoagulation, and in
acute thrombosis, early anticoagulation therapy attains com-
plete recanalization in up to 35%–45% of patients [1–3]. The
role of anticoagulants in the treatment of chronic PVT is dis-
puted [4]. The effectiveness of anticoagulant treatment has
been shown to be dependent, among other things, on the
extent of the thrombosis, the presence of ascites, and the
delay from onset of symptoms to beginning of treatment
[5–8]. If anticoagulant treatment fails, more invasive proce-
dures can be considered. However, there is paucity of
evidence to firmly guide when and which patients benefit
from more aggressive treatment, e.g., thrombolysis. Extensive
thrombosis, delayed start of anticoagulation treatment, and
more than one thrombophilic risk factor have been sug-
gested as indications for early more invasive treatment; how-
ever, the results have been inconsistent [2,9–15].
The aim of this study was to examine and compare treat-
ment outcomes in patients treated for PVT in a large health
care district, in order to find predictors of insufficient recanal-
ization and portal hypertensive complications.
Materials and methods
Patients and methods
This retrospective cohort study included patients diagnosed
with PVT in Helsinki and Uusimaa health care district’s
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hospitals (HUS). HUS-area serves a population of 1.6 million
people in a defined geographical area of 9216 km2 in south-
ern Finland and includes 18 secondary and one tertiary refer-
ral hospitals with approximately 2500 hospital beds. These
public hospitals treat all referral patients within the area,
whereas private referral hospitals treating these patients are
non-existent. All HUS-area hospitals use the same electronic
patient record system. Patients diagnosed with PVT in any of
the HUS area hospitals between 2006 and 2015 were identi-
fied from electronic patient records by an electronic search
for the International Classification of Diseases 10 (ICD-10)
code I81 (PVT). Exclusion criteria were liver cirrhosis, malig-
nancy, peritransplantation PVT, age below 18 years, primary
treatment outside HUS district, and cavernous transformation
at baseline. Patients with thrombus in the splenic or the
superior mesenteric vein not extending to the portal vein
were also excluded.
Institutional review board of HUS approved the study
plan and gave permission to conduct the study. Patient
records were analyzed and data regarding patient character-
istics, hospital stay, treatment, and outcome were manually
extracted. Last date of follow-up was defined as the date of
last note in the electronic patient records. The patient
records were reviewed up to 26 September 2019.
Definitions
The primary endpoints were insufficient recanalization and
the incidence of portal hypertensive complications.
Insufficient recanalization was defined as partial or total
obstruction, or a cavernous transformation of the portal vein
at last imaging. Portal hypertensive complications were
defined as ascites, esophageal or fundus varices, or symp-
tomatic portal biliopathy defined as jaundice needing an
intervention together with compatible cholangiog-
raphy findings.
Age of thrombosis was determined according to the ana-
tomic-functional classification used by Sarin et al. [26]. Acute
thrombosis was defined either as a symptomatic thrombosis
detected for the first time in a previously patent vein, the
presence of hyperdense thrombus on imaging or absent or
limited collateral circulation and dilated portal vein at the
site of occlusion. Sub-acute thrombosis was defined similarly
except that instead of symptomatic, it was asymptomatic.
Chronic thrombosis was defined as no hyperdense thrombus,
a previously diagnosed PTV on follow-up, portal cavernoma,
or clinical features of portal hypertension.
Statistical analyses
All statistical analyses were performed using IBM SPSS
Statistics version 23 (IBM Corp#, Armonk, NY, USA). Cox
regression analysis was used for univariate and multivariate
analyses. Variables with p values <.2 in univariate analysis
were selected for multivariate analysis, except for variables
that could be expected to cause multicollinearity and those
with 10% or more variables missing. Kaplan–Meier estimates
were used for survival or cumulative incidence of outcome
events during follow-up. A two-tailed p-value below .05 was
considered statistically significant.
Results
Patient characteristics and onset of disease
The initial extraction yielded 402 patients with a diagnosis of
PVT. After exclusions, the final study cohort comprised 145
patients (Figure 1). Information on patient characteristics and
the onset of disease are shown in Table 1. The median age
was 53 years, and the majority were male (n¼ 98, 68%). Of
all patients, 83 (57%) had no comorbidities and 22 (15%) had
anticoagulation or antithrombotic treatment at onset.
Etiology
Etiology was multifactorial in 43% (n¼ 63) of patients (Table
2). Most common etiological factors were thrombophilia
(n¼ 86, 59%) and inflammatory disease (n¼ 66, 46%).The most
common inflammatory disease was acute pancreatitis (n¼ 20,
14%). In 13 (9%) patients, no etiological factor was found.
Treatment and outcome
Baseline imaging results are shown in Table 3. Ascites was pre-
sent in baseline imaging in 29% (n¼ 42). There was only 1
patient (0.7%) with varices at baseline. Diagnostic imaging was
ultrasound in 30 (20%) patients, CT with contrast in 110 (76%)
patients, and MRI in 6 (4%) patients. Last imaging was done
less than 6months from diagnosis in 35 (24%) patients,
6–9months from diagnosis in 14 (10%) patients, 9–12months
in 5 (3%) patients, 12–18months in 11 (8%) patients, and more
than 18months from diagnosis in 62 (43%) patients. No follow-
up imaging was done in 18 (12%) patients after diagnosis.
First treatment modality was unfractionated heparin in 21
(15%) of patients, thrombolysis in 2 (1%), and surgery in 4
(3%) patients (Table 4). The rest (n¼ 111, 77%) had anticoa-
gulation (other than unfractionated heparin) as first treat-
ment or had no treatment (n¼ 7, 5%). Second intervention
was needed in 14 (10%) patients, and a third or fourth was
needed in 3 (2%) patients. Bowel resection, due to the devel-
opment of intestinal infarction, was needed in 4 (3%)
patients, on average 24 h (median) after PVT diagnosis. On
three (2%) patients, it was the primary intervention and only
one (1%) patient needed late bowel resection. In addition to
these, four (3%) thrombectomies via laparotomy and two
(1%) explorative laparotomies were done because either the
clinical condition (n¼ 3) or CT findings (n¼ 2) raised suspi-
cion of intestinal infarction.
Kaplan–Meier estimates for complete recanalization were
21% at 6months, 29% at 1 year, 35% at 2 years, and 42% at
5 years follow-up. For partial or complete recanalization, cor-
responding Kaplan–Meier estimates were 32% at 6-month,
45% at 1-year, 56% at 2-year, and 64% at 5-year follow-up.
Kaplan–Meier estimates for cavernous changes were 1% at 6-
month, 6% at 1-year, and 18% at 2-year follow-up.
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Among patients with complete thrombosis at baseline,
Kaplan–Meier estimates for complete and partial thrombosis
at 2-year follow-up were 32% and 14%, respectively. For
patients with baseline partial thrombosis, 25% progressed to
complete thrombosis by 2 years.
Anticoagulation was continued for a median time of 8
months (IQR 5–12) and was continued indefinitely for 61
(42%) patients. Of those with a thrombophilic state, 22 (73%)
had anticoagulation continued indefinitely, while the rest
(27%) had it only continued temporarily.
Portal hypertensive complications
A total of 40 (28%) patients with either cavernous changes
(n¼ 27), total obstruction (n¼ 6), or partial obstruction
(n¼ 7) at the end of follow-up developed new-onset portal
hypertensive complications: ascites in 11 (8%) patients (5
requiring treatment) and esophageal varices in 30 (21%),
with 8 (6%) having variceal bleeding (esophageal).
Symptomatic portal biliopathy developed in 2 (1%) patients.
Of those 42 patients (29%) that had ascites at baseline, 1
developed ascites in follow-up and altogether 19 developed
portal hypertensive complications. Kaplan–Meier estimates
for the development of new-onset portal hypertensive com-
plications at 5 and 10 years respectively were 31% and 42%.
Gastroscopy was done to a total of 67 (46%) patients during
follow-up, and all varices were confirmed with gastroscopy.
Complications and recurrences
Bleeding likely associated with anticoagulation was the only
type of treatment complication observed (in the group).
Gastrointestinal bleeding was the most common type of
complication (n¼ 13, 9%), of which nine originated from the
esophagus and four from the ventricle (fundus n¼ 3, corpus
n¼ 1), all diagnosed by gastroscopy. Other bleeds (n¼ 12,
8%) included intramuscular hematomas (n¼ 5) and nose
bleeds (n¼ 7). During follow-up, 5 (3%) patients had more
than one bleeding episode (Table 4).
PVT recurrence developed in 6 (4%) patients after a
median 2.4 years from baseline (IQR 0.9–10.2), and 8 (6%)
patients had other thromboembolic conditions during fol-
low-up (Table 4).
Multivariate analysis
Sub-acute or chronic thrombosis (HR 3.1, 95% CI 1.6–5.8) was
independently associated with insufficient recanalization,
while acute pancreatitis at baseline (HR 0.3, 95% CI 0.2 0.7)
was a protective factor. Kaplan–Meier estimates for complete
recanalization at 3 years were 47% if the thrombosis was
acute and 16% in sub-acute or chronic. If the patient had
acute pancreatitis, the Kaplan-Meier estimate for recanaliza-
tion at 3 years was 72% versus 29% if the patients did not
have acute pancreatitis (Figure 2, Supplementary Table 1).
Figure 1. Flowchart of patient selection. HUS: Helsinki University Hospital.
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Independent predictors of incident portal hypertensive
complications were ascites at baseline (HR 3.3, 95% CI
1.7–6.7), sub-acute, or chronic thrombosis (HR 2.9, 95%
CI1.6–5.3), extension of thrombosis to the splenic or mesen-
teric vein (HR 2.6, 95% CI 1.2–5.7), myeloproliferative disease
(HR 3.0, 95% CI 1.4–6.5), and anemia (HR 2.1, 95% 1.1–3.9),
while acute pancreatitis at baseline was a protective factor
(HR 0.1, 95% CI 0.03–0.5).
Kaplan–Meier estimates for the development of portal
hypertensive complications at 5 years was 43% if ascites was
present at baseline and 26% if it was not. In acute thrombosis,
Kaplan–Meier estimate for the development of portal hyper-
tensive complications was 22% and 47% in non-acute throm-
bosis. In a thrombosis extending to the superior mesenteric
vein or the splenic vein, Kaplan–Meier estimates for the devel-
opment of portal hypertensive complications at 5 years were
35% versus 25% in thrombosis only extending to the portal
vein. If the patient had a myeloproliferative disease,
Kaplan–Meier estimate for the development of portal hyper-
tensive complications was 56% versus 27% if the patient did
not have a myeloproliferative disease. If the patient had
anemia, Kaplan–Meier estimate for the development of portal
hypertensive complications at 5 years was 37% versus 27% if
the patient did not have anemia at baseline. If the patient
had acute pancreatitis, Kaplan–Meier estimate for the develop-
ment of portal hypertensive complications at 5 years was 17%
versus 33% if the patient did not have acute pancreatitis at
baseline (Figure 3(A–C), Supplementary Table 2).
Survival
Median clinical follow-up time was 6.9 years (IQR 5.3–9.4,
range 3.8–13.7) and 12 (8%) patients died within 90 days.
Table 1. Basic demographics and onset.
N (%)
n¼ 145
Age, median (IQR) 52.8 (41.9–63.7)
Sex, Female n (%) 47 (32%)
Comorbidity, n (%)
Diabetes 15 (10%)
Previous deep vein thrombosis 12 (8%)
Other comorbiditya 36 (25%)
No comorbidity 83 (57%)




Antithrombotic medicationc 15 (10%)
Hormone therapy
Indication: contraception 12 (8%)
Indication: menopause 3 (2%)
Incidentald 12 (8%)
Laboratory results at diagnosis, n (%)








Normal (<0.5mg/l) 3 (7%)
Elevated (>0.5mg/l) 37 (93%)
Elevated liver enzymesf,k 65 (45%)
eGFR < 90ml/min/1.73m2 48 (33%)
eGFR: estimated glomerular filtration rate; IQR: interquartile range.
ahypertension (n¼ 26), atrial fibrillation (n¼ 10), coronary artery disease
(n¼ 6), previous stroke (n¼ 4), previous acute myocardial infarction (n¼ 1),
congestive heart failure (n¼ 3), atherosclerosis (n¼ 2), chronic obstructive pul-
monary disease (n¼ 2), kidney failure (n¼ 1), previous pulmonary embolism
(n¼ 2), Alzheimer (n¼ 2).
bIndication for anticoagulation: atrial fibrillation (n¼ 5), previous thrombo-
embolism (n¼ 1), postoperative thrombosis prophylaxis (n¼ 1).
cIndication for antithrombotic medication: myeloproliferative disease (n¼ 3),
coronary artery disease (n¼ 4), not known (n¼ 8).
dPortal vein thrombosis found incidentally during imaging for other purposes.
eD-dimer determined in 40 patients.
fAspartate aminotransferase and/or alanine aminotransferase determined in
138 patients.
gwomen < 117g/l, men < 134g/l.
hwomen > 155g/l, men > 167g/l.
i<1,50,109/l.
j>3,60,109/l.
kwomen: aspartate aminotransferase >35 U/l, men: aspartate aminotransferase
>45 U/l and/or women: alanine aminotransferase >35 U/l, men: alanine ami-
notransferase >50 U/l.
Table 2. Prevalence of etiological factors.
N (%)
n¼ 145
Number of etiological factors
No etiological factors found 13 (9%)
1 etiological factor 69 (48%)
2 etiological factors 57 (39%)
3 etiological factors 5 (3%)
4 or more etiological factors 1 (1%)
Hematological disease 18 (12%)
JAK V617F 2 (1%)
Polysytemia vera 1 (1%)
Essential thrombocytosis 1 (1%)
JAK V617Fþ polysytemia vera 9 (6%)
JAK V617Fþ Essential thrombocytosis 5 (3%)
Genetic mutation 12 (7%)
Factor V Leiden mutation 7 (5%)
Factor II mutation 3 (2%)
Both mutations 2 (1%)
Thrombophilia 86 (59%)
Factor VIII > 160% 38 (26%)
Protein S < 65% 34 (23%)
Protein C < 74% 24 (17%)
Antithrombin 3< 85% 29 (20%)
Cardiolipin antibodies positive 20 (14%)
Beta-2 glycoprotein 1 antibodies positive 5 (3%)
More than one pro-coagulative finding 42 (29%)
No pro-coagulative finding 59 (41%)
Inflammatory disease alone 66 (46%)
Acute pancreatitisd 20 (14%)
Cholecystitise 12 (8%)
Acute-on-chronic pancreatitis 11 (8%)
Intra-abdominal abscess 8 (6%)
Diverticulitis 2 (1%)






Other possible reasonsc 13 (9%)
No etiologic factor found 13 (9%)
JAK V617F: Janus kinase 2 gene mutation; GI: gastrointestinal.
aCholangitis (n¼ 2), appendicitis (n¼ 2), sepsis (n¼ 2), pouchitis (n¼ 1),
ischaemic colitis (n¼ 2), ileitis (n¼ 1) Crohn’s disease (n¼ 1), infection NAS
(n¼ 1), postoperative infection of anal fistula (n¼ 1).
bPancreatic resection for necrotizing pancreatitis, no vascular reconstruction
(n¼ 1), appendicectomy (n¼ 1), proctocholectomy (n¼ 1).
cSepsis (n¼ 2), obesity (n¼ 3), secondary polysytemia (n¼ 1), Osler-Weber-
Rendu syndrome (n¼ 1), Klippel-Trenaunay syndrome (n¼ 1), hereditary
spherocytosis (n¼ 2), hepatitis (n¼ 1), AIDS (n¼ 1), acute liver failure (n¼ 1).
dAtlanta classification: mild (n¼ 1), moderately severe (n¼ 12), severe (n¼ 7).
eChronic (n¼ 7), acute (n¼ 5).
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Deaths were due to PVT (n¼ 1), myocardial infarction (n¼ 3),
sepsis (n¼ 2), pancreatitis (n¼ 1), and pneumonia (n¼ 1).
The rest (n¼ 4) were unknown. Kaplan–Meier survival esti-
mates were 90%, 88%, and 82% at 1 year, 3 years, and 5
years, respectively. Two PVT-related deaths occurred in fol-
low-up, which were 8 days (bowel ischemia) and 4.5 years
after diagnosis (bowel ischemia due to the development of a
new PVT).
Discussion
Treatment of PVT remains a challenge, as we found that
complete recanalization under mainly anticoagulation ther-
apy is achieved in only 42% of patients and 31% develop
new portal hypertensive complications in a 5-year follow-up
period (ascites, esophageal varices, or symptomatic portal bil-
iopathy). Non-acute thrombosis was an independent risk fac-
tor for insufficient recanalization, and acute pancreatitis was
a protective factor. Ascites at baseline, non-acute thrombosis,
thrombosis extending to the superior mesenteric vein or the
splenic vein, myeloproliferative disease, and anemia were risk
factors for portal hypertensive complications, while acute
pancreatitis was a protective factor. Thus, patients with these
risk factors might be candidates for more aggressive therapy,
i.e. thrombolysis via either superior mesenteric artery or
transjugular intrahepatic portosystemic shunt (TIPS) [16–19].
EASL guidelines recommend anticoagulation therapy in all
patients with acute PVT [20], while ACCP guidelines recom-
mend anticoagulation in symptomatic patients only [21]. It is
noteworthy that neither guideline recommend thrombolysis
for treatment of PVT, even though, as we show here, one-
third will develop portal hypertensive complications and over
half of PVTs are not completely recanalized within 5 years.
ESVS guidelines conclude that there is not yet enough evi-
dence to support recommendations for endovascular thera-
pies. Both ESVS and ESTES guidelines recommend
Table 3. Characteristics of thrombosis at the time of diagnosis and treatment.
N (%)




Extent of thrombosis, n (%)
PV alone 56 (39%)
PVþ SMV 32 (36%)
PVþ SV 16 (22%)
PVþ SMVþ SV 41 (28%)




Varices at baseline 1 (0.7%)
Ascites at baseline imaging 42 (29%)
First treatment modality, n(%) 138 (95%)
Anticoagulation (other than unfractionated heparin)b 111 (77%)
Unfractionated heparin 21 (15%)
Thrombolysis 2 (1%)
Surgeryc 4 (3%)
Second treatment modality, n(%) 14 (10%)
Unfractionated heparin 12 (8%)
Endovascular thrombectomy 2 (1%)
Third treatment modality, n(%) 2 (1%)
Unfractionated heparin 2 (1%)
Fourth treatment modality, n(%) 1 (1%)
Thrombolysis 1 (1%)
PV: portal vein; SMV: superior mesenteric vein; SV: splenic vein.
aAcute¼ first-time detected portal vein thrombosis in previously patent portal
vein, the presence of hyperdense thrombus on imaging, absent, or limited
collateral circulation, dilated portal vein at the site of occlusion, symptomatic.
Sub-acute¼ first-time detected portal vein thrombosis in previously patent
portal vein, the presence of hyperdense thrombus on imaging, absent, or lim-
ited collateral circulation, dilated portal vein at the site of occlusion, asymp-
tomatic. Chronic¼ no hyperdense thrombus; previously diagnosed PVT on
follow-up, portal cavernoma, and clinical features of portal hypertension.
bLow-molecular-weight heparin (n¼ 104), Warfarin (with low-molecular-weight
heparin used a bridge) (n¼ 7).
cThrombectomy via laparotomy (n¼ 4).
Table 4. Outcomes and complications.
N (%)
n¼ 145
Follow-up results of treatment




Thrombosis at 4–8 months (n¼ 84)
No thrombosis 21 (15%)
Partial thrombosis 36 (25%)
Complete thrombosis 16 (11%)
Cavernoma 11 (8%)
No imaging at this time 61 (42%)
Thrombosis at 10–14 months (n¼ 72)
No thrombosis 27 (19%)
Partial thrombosis 24 (17%)
Complete thrombosis 6 (4%)
Cavernoma 15 (10%)
No imaging at this time 73 (50%)
Thrombosis at last imaging control (n¼ 127)
No thrombosis 49 (34%)
Partial thrombosis 23 (16%)
Complete thrombosis 15 (10%)
Cavernoma 40 (28%)
No follow-up imaging or died 18 (12%)
Last imaging modality 7 (7%)
CT, no contrast 9 (6%)
CT with contrast 52 (36%)
MRI 7 (5%)
Ultrasound, no Doppler 37 (26%)
Ultrasound with Doppler 22 (15%)
Imaging done for follow-up of PVT 69 (48%)
Clinical follow-up, median (IQR) 6.9 (5.3 9.4) years
Radiologic follow-up, median (IQR) 1.3 (0.4 4.6) years
New-onset portal hypertensive complications 40 (28%)
Ascites 11 (8%)
Only visible on imaging 6 (4%)
Requiring treatment 5 (3%)
Varices 30 (21%)
Varices without bleeding 22 (15%)
Variceal bleeding 8 (6%)
Symptomatic portal biliopathy 2 (1%)
Recurrence of portal vein thrombosisa 6 (4%)




Upper limb thrombosis 2 (1%)
Deep vein thrombosisþ PE 2 (1%)
Complicationsc 25 (17%)
GI bleeding 13 (9%)
Other bleedb 12 (8%)
More than one bleed 5 (3%)
PE: pulmonary embolism; DVT: deep-vein thrombosis; GI: gastrointestinal.
aTreatment: UFH (n¼ 2), LMWH dose raised (n¼ 1), argatroban infu-
sion (n¼ 1).
bIntramuscular hematoma (n¼ 5), epistaxis (n¼ 7).
cAll bleedings were considered to be related to anticoagulation treatment.
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endovascular intervention for patients with venous acute mes-
enteric ischemia if the patients’ condition deteriorates during
medical therapy, although ESVS guidelines recommend this
only if the patient is a poor surgical candidate [22,27].
Only a few studies have analyzed risk factors for insuffi-
cient recanalization. In a European prospective multicenter
study, Plessier et al. [6] analyzed 102 patients with acute,
non-cirrhotic PVTs, and identified ascites and thrombosis
extending to the splenic vein as independent risk factors for
insufficient recanalization. In fact, recanalization of the portal
vein did not occur in any of the patients with both of these
risk factors [6]. In our material, ascites and extensive throm-
bosis did not reach statistical significance as risk factors for
insufficient recanalization. There were 23 (16%) patients with
ascites and thrombosis extending to the splenic vein. Of
these, 7 (30%) recanalized completely, 2 achieved partial
recanalization (9%), and 14 (61%) achieved no recanalization.
However, both ascites at baseline and extensive throm-
bosis (extending to the superior mesenteric vein or the
splenic vein) were risk factors for the development of portal
hypertensive complications.
In another retrospective multicenter study in Spain,
Turnes et al. [5] included 38 patients with acute non-cir-
rhotic, non-malignant PVTs and found a delay in initiating
anticoagulation associated with lack of recanalization.
Patency of portal vein was achieved in 39%44% of patients
treated with anticoagulation in these studies [5–6], and por-
tal hypertensive complications occurred in 55% [5]. Our
results are in line with these reports, but we also identified
acute pancreatitis as a protective factor. The protective effect
of acute pancreatitis is most likely due to the transitory
nature of inflammation as a hypercoagulative state. Out of
the 20 patients with acute pancreatitis, 3 had a genetic
mutation and none had a myeloproliferative disease. Taking
out those with a double diagnosis did not change the correl-
ation between acute pancreatitis and outcome.
Recently, there has been increasing interest toward inter-
ventional treatment of acute PVT. A systematic review com-
prising 399 patients with PVT reported outcomes of TIPS
combined with either catheter-directed thrombolysis or
thrombectomy or both. TIPS was technically feasible in 95%
of patients with 10% complication rate and 79% 12-month
recanalization rate [17]. However, most of the patients in this
meta-analysis were cirrhotic (92%).
Few studies have reported outcomes of interventional
treatment of non-cirrhotic, non-malignant PVT. Klinger et al.
[14] treated 17 consecutive patients with a combination of
transjugular thrombectomy, local thrombolysis, and used
combined TIPS selectively. Recanalization was achieved in
94%, 2-year patency rate was 88%, and none developed por-
tal hypertensive complications. A total of 94% had concomi-
tant superior mesenteric vein and 88% splenic vein
thrombosis in addition to complete PVT. A report by Wolter
et al. [19] included seven patients with non-cirrhotic non-
malignant PVT in whom TIPS combined with local thromb-
olysis and thromboaspiration was used with patency rate of
71%. All patients had splenic vein and/or superior mesenteric
vein thrombosis in addition to complete PVT. Thus, both of
these series used invasive intervention mainly on patients
who had risk factors for both insufficient recanalization (com-
plete PVT) and portal hypertensive complications (concomi-
tant superior mesenteric vein and/or splenic
vein thrombosis).
Interventional treatment was used scarcely in our material.
There were five endovascular procedures (three thrombolysis
and two thrombectomies) and four surgical operations
(thrombectomy via laparotomy). Although there has been
concern of safety of interventional treatment, we did not
Figure 2. Predictors of insufficient recanalization divided by (a) age of thrombosis and (b) etiology (acute pancreatitis).
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have any complications from neither endovascular nor surgi-
cal procedures. Thrombolysis was performed through a cath-
eter in the superior mesenteric artery accessed through the
femoral artery. Two of these patients achieved full recanaliza-
tion, while one developed cavernous changes. One patient
developed portal hypertensive complications. Endovascular
thrombectomy was performed through a transhepatic punc-
ture, and both of these patients achieved full recanalization
and did not develop portal hypertensive complications. All of
those with surgical thrombectomies achieved complete
recanalization and did not develop portal hypertensive
complications.
Figure 3. (A) Predictors of portal hypertensive complications divided by (a) age of thrombosis and (b) etiology (myeloproliferative disease). (B) Predictors of insuffi-
cient recanalization divided by (a) etiology (acute pancreatitis) and (b) extent of thrombosis (two vs. one obstructed vein). (C) Predictors of insufficient recanaliza-
tion divided by (a) anemia and (b) ascites.
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Although interventional treatment options for PVT have
showed promising results in recent studies [9,14,15,19,23],
there is no consensus on which patients benefit most from
these [2]. Since anticoagulation is a safe and effective option
in the majority of cases, utilization of more invasive methods
should be evaluated carefully [3,8,24].
Chronic thrombosis has been suspected to recanalize
poorly with anticoagulation treatment. This was true in our
study as well, as we found both sub-acute and chronic
thrombosis to be predictors of insufficient recanalization.
Thrombosis extending to the splenic or superior mesen-
teric vein was found to predict incident portal hypertensive
complications but did not reach statistical significance as a
predictor of insufficient recanalization. In localized PVT, for-
mation of porto-portal collaterals may restore portal flow in
a few weeks. Conversely, restoration of venous flow in
thrombosis extending to the splenic or mesenteric veins
likely requires the formation of larger porto-systemic collater-
als, and despite these collaterals, significant portal hyperten-
sion may still persist and thereby predispose to portal
hypertensive complications.
The study by Sogaard et al. [3] concluded that follow-up
of patients with PVT should be well organized, due to the
high risk of development of portal hypertension. We agree
with this statement and see room for improvement in our
own health care district. Our study included 35 patients with
no follow-up imaging (or gastroscopy) performed after six
months. Though it is not possible to recommend optimal fol-
low-up time based on our study alone, we believe gastros-
copy should be performed on all patients at the latest
3months from diagnosis.
This study has limitations. As a retrospective study, there
is an inherent risk of information bias and misclassifications.
Incidence and prognosis might be underestimated due to
misdiagnosis and miscoding of patients with PVT. For
example, there is clinical knowledge to support that some
patients with, for example a simultaneous pancreatitis diag-
nosis, might not be recorded with a separate I81 diagnosis
code. Due to this some of the patient fitting, the criteria
might not be included in the search.
The radiological follow-up period varied a lot within our
sample and up to 24% of patients had no follow-up imaging
done after 6months from diagnosis. PVT is known to achieve
recanalization after 6months, and therefore, lack of follow-up
imaging might cause results to seem more pessimistic than
they really are. We tried to minimize the potential effect of
this by using Kaplan–Meier survival analysis in our out-
come analyses.
There are several guidelines for the treatment of PVT
[17,21,22,25], yet it is still somewhat unclear which patients
and types of PVTs are in risk of insufficient recanalization. In
our study, we found that patients with non-acute PVTs were
less likely to recanalize sufficiently, whereas acute pancrea-
titis was a protective factor from this. We also found that
patients with ascites at baseline, a myeloproliferative disease,
a non-acute, extensive PVT, and anemia at baseline were
more likely to develop portal hypertensive complications,
whereas acute pancreatitis was a protective factor from this.
Based on our findings, the age, etiology, and extent of
thrombosis should be considered when deciding on the
treatment and follow-up of PVT.
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